An illuminating essay by Byron Richards, author of Fight for Your Health: Exposing the FDA’s Betrayal of America, should be required reading for every member of Congress before voting Yes or NO on the appointment of Dr. Andrew von Eschenbach, who is poised to head the FDA.
A notice from The American College of Neuropsychopharmacology, the inner sanctum of biological–predominantly drug-centered psychiatry–informs the
membership of the resignation of Dr. Charles Nemeroff, the Editor-in-Chief of its journal, Neuropsychopharmacology.
A Boston Globe report (below) focuses on three recent reports in the Journal of the American Medical Association (JAMA) by Harvard researchers who violated the journal’s disclosure policy by failing to disclose their financial ties to companies that had the most to gain from their purported findings.
Steven Potkin, who, LAT reports, is a brother-in-law of Jane Pauley who wrapped up her career as TV news anchor to become a paid drug pusher.
Congressional leaders have lost patience with the cat and mouse game being played by officials of the National Institutes of Health.
The harm done by journals’ failure to protect the integrity of science can hardly be overstated.
Today’s New York Times editorial hits the mark–it’s right on target!
The Associated Press reports (1, 2 below) that the FDA has just issued new warnings about two additional life-threatening risks induced by SSRI antidepressants: Serotonin Syndrome and Persistent Pulmonary Hypertension in newborn babies.
The latest investigative report focusing on financial conflicts of interest by Pulitzer Prize winner, David Willman of the Los Angeles Times, reveals that even as the NIH director, Dr. Elias Zerhouni, announced publicly last year that scientists at the National Institutes of Health would be barred from accepting consulting fees from industry, evidence shows that the ban is clearly not being enforced.
Following on the heels of an investigative report by David Armstrong of The Wall Street Journal <https://ahrp.org/cms/content/view/286/27/> the Associated Press reports that JAMA claims it was misled.
Two probing first rate investigative reports document how psychiatry’s treatments are shaped by "opinion leaders" whose professional recommendations are compromised by their substantial, largely undisclosed, financial ties to drug companies.
An investigative report in Mercury News (below) focuses on Stanford University department heads, associate deans and other leaders because “these are senior people who set the tone at the medical school and are role models for junior faculty members.”
